Cargando…

Determining drug dose in the era of targeted therapies: playing it (un)safe?

Targeted therapies against phosphatidylinositol 3-kinase (PI3K), Bruton’s tyrosine kinase (BTK), and B-cell lymphoma-2 (BCL-2) are approved for chronic lymphocytic leukemia (CLL). Since approval of the first-in-class drugs, next-generation agents have become available and are continuously under deve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Skånland, Sigrid S., Tjønnfjord, Geir E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399108/ https://www.ncbi.nlm.nih.gov/pubmed/35999205 http://dx.doi.org/10.1038/s41408-022-00720-7

Ejemplares similares

Cryopreservation of primary B cells minimally influences their signaling responses
por: Hermansen, Johanne U., et al.
Publicado: (2018)

Ex vivo drug sensitivity screening in multiple myeloma identifies drug combinations that act synergistically
por: Giliberto, Mariaserena, et al.
Publicado: (2022)

Functional testing of relapsed chronic lymphocytic leukemia guides precision medicine and maps response and resistance mechanisms. An index case
por: Skånland, Sigrid S., et al.
Publicado: (2022)

Single cell profiling of phospho-protein levels in chronic lymphocytic leukemia
por: Myhrvold, Ida K., et al.
Publicado: (2018)

P613: ANALYSIS OF EX-VIVO RESPONSE TO SINGLE DRUGS AND DRUG COMBINATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENT SAMPLES
por: Miranda Santana, Leonardo, et al.
Publicado: (2023)

A tumor microenvironment model of chronic lymphocytic leukemia enables drug sensitivity testing to guide precision medicine
por: Hermansen, Johanne U., et al.
Publicado: (2023)

Mcl‐1 and Bcl‐xL levels predict responsiveness to dual MEK/Bcl‐2 inhibition in B‐cell malignancies
por: Melvold, Katrine, et al.
Publicado: (2021)

PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here?
por: Skånland, Sigrid S., et al.
Publicado: (2022)

Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors
por: Tjønnfjord, Geir E, et al.
Publicado: (2007)

Primary chronic cold agglutinin disease: An update on pathogenesis, clinical features and therapy
por: Berentsen, Sigbjørn, et al.
Publicado: (2007)

T‐helper cell regulation of CD45 phosphatase activity by galectin‐1 and CD43 governs chronic lymphocytic leukaemia proliferation
por: Imbery, John F., et al.
Publicado: (2022)

Successful Control of Hepatitis B Virus Reactivation following Restart of Ibrutinib in Chronic Lymphocytic Leukaemia
por: Tjønnfjord, Sara Kristina Viberg, et al.
Publicado: (2021)

In the Era of Systemic Therapy for Hepatocellular Carcinoma Is Transarterial Chemoembolization Still a Card to Play?
por: Bucalau, Ana-Maria, et al.
Publicado: (2021)

Cold agglutinin disease: current challenges and future prospects
por: Berentsen, Sigbjørn, et al.
Publicado: (2019)

Are inflatable play structures really safe for our children?
por: Corominas, L., et al.
Publicado: (2018)

Vasopressors and Nutrition Therapy: Safe Dose for the Outset of Enteral Nutrition?
por: Simo˜es Covello, Luís Henrique, et al.
Publicado: (2020)

Successful treatment of subcorneal pustular dermatosis targeting an underlying monoclonal IgA gammopathy
por: Kreyberg, Ina, et al.
Publicado: (2023)

“Playing it SAFE in the NICU” SAFE-R: a targeted diagnostic ultrasound protocol for the suddenly decompensating infant in the NICU
por: Yousef, Nadya, et al.
Publicado: (2021)

Qualifications of Safe Return to Play Criteria
por: Ercan, Sabriye, et al.
Publicado: (2017)

Targeted antimicrobial therapy in the microbiome era
por: Stone, V.N., et al.
Publicado: (2017)

SNX4 in Complex with Clathrin and Dynein: Implications for Endosome Movement
por: Skånland, Sigrid S., et al.
Publicado: (2009)

REDEPLOYMENT IN A BELFAST COVID CENTRE: PLAYING IT SAFE OR PLAYING WITH FIRE
por: Kempf, Bjoern, et al.
Publicado: (2021)

Is the use of RAS inhibitors safe in the current era of COVID-19 pandemic?
por: Park, Sungha, et al.
Publicado: (2020)

How safe is BDSM? A literature review on fatal outcome in BDSM play
por: Schori, Anouk, et al.
Publicado: (2021)

Towards safe and sustainable innovation in nanotechnology: State-of-play for smart nanomaterials
por: Gottardo, Stefania, et al.
Publicado: (2021)

Management of Melanoma Brain Metastases in the Era of Targeted Therapy
por: Shapiro, Daniela Gonsalves, et al.
Publicado: (2011)

Safe and Valuable Endoscopy in the COVID Era
por: Libânio, Diogo, et al.
Publicado: (2020)

Autoimmune Complications in Chronic Lymphocytic Leukemia in the Era of Targeted Drugs
por: Vitale, Candida, et al.
Publicado: (2020)

Commentary: Playing it safe versus being responsible
por: Ravilla, Thulasiraj
Publicado: (2019)

Cytoreductive surgery in the era of targeted molecular therapy
por: Thomas, Arun Z., et al.
Publicado: (2015)

Melanoma Brain Metastases in the Era of Target Therapies: An Overview
por: Becco, Paolo, et al.
Publicado: (2020)

Chemotherapy, targeted therapy and immunotherapy: Which drugs can be safely used in the solid organ transplant recipients?
por: Maggiore, Umberto, et al.
Publicado: (2021)

Targeted DNA vaccines eliciting crossreactive anti-idiotypic antibody responses against human B cell malignancies in mice
por: Ruffini, Pier Adelchi, et al.
Publicado: (2014)

The Era of Nanomaterials: A Safe Solution or a Risk for Marine Environmental Pollution?
por: Esposito, Maria Consiglia, et al.
Publicado: (2021)

S144: BTK AND BCL-2 ACTIVITY AT BASELINE PREDICTS MRD STATUS FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH IBRUTINIB + VENETOCLAX IN THE HOVON 141/VISION TRIAL
por: Urban, Aleksandra, et al.
Publicado: (2023)

National trends in incidence and survival of chronic lymphocytic leukemia in Norway for 1953–2012: a systematic analysis of population‐based data
por: Lenartova, Andrea, et al.
Publicado: (2016)

Advances in targeted and immunobased therapies for colorectal cancer in the genomic era
por: Seow, Heng Fong, et al.
Publicado: (2016)

Infections in Patients with Rheumatoid Arthritis in the Era of Targeted Synthetic Therapies
por: Thomas, Konstantinos, et al.
Publicado: (2020)

Safe Pulmonary Scintigraphy in the Era of COVID-19
por: Zuckier, Lionel S.
Publicado: (2022)

Defining disease modification in myelofibrosis in the era of targeted therapy
por: Pemmaraju, Naveen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i5evdgfafa1lu3ndlbkb4crucc